Osimertinib + chemo improves progression-free survival in advanced non-small cell lung cancer: Study

by

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study publishedonline Nov. 8 in the New England Journal of Medicine.

Leave A Comment

Your email address will not be published. Required fields are marked *